NCT06548100View on ClinicalTrials.gov

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

July 14, 2026

Study Completion Date

November 3, 2026

Conditions

Generalized Lipodystrophy

Interventions

DRUG

mibavademab

Administered by intravenous (IV) infusion followed by subcutaneous (SC) injection

Trial Locations (2)

20892

National Institutes of Health, Bethesda

48109

University of Michigan, Ann Arbor

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06548100 - A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) | Biotech Hunter | Biotech Hunter